Johnson & Johnson Q3 2026 Earnings: Sales Growth Contrasts with GAAP Profit Decline

Johnson & Johnson (NYSE: JNJ) reported Q3 2026 sales of $25.399 billion, up 5.9% from $23.993 billion, while diluted GAAP EPS fell to $0.09 from $2.12. A proposed talc litigation resolution and charges associated with Firefly Bio and Sail Biomedicines weighed on reported earnings; adjusted EPS also declined 7.5% to $2.59 as higher R&D spending and a lower gross margin offset revenue growth. The company raised its full-year 2026 sales and adjusted EPS guidance.

Core Financial Results

Reported sales growth was similar on an operational basis, at 6.0%, while adjusted operational growth was 6.1%. Currency reduced reported growth by only 0.1 percentage point, indicating that the increase largely reflected underlying business performance.

Profit moved in the opposite direction. Gross profit increased more slowly than sales, adjusted net earnings declined, and special items reduced GAAP net earnings to $210 million.

Operational sales growth excludes currency translation. Adjusted operational growth also excludes the net effect of acquisitions and divestitures, while adjusted earnings exclude intangible amortization and specified special items.

Business and Segment Performance

Innovative Medicine remained the main growth engine, while MedTech grew more slowly. The U.S. business also expanded considerably faster than international markets.

Innovative Medicine growth came from TREMFYA and newer immunology products; oncology products including DARZALEX, CARVYKTI, TECVAYLI, RYBREVANT/LAZCLUZE and ERLEADA; and neuroscience products SPRAVATO and CAPLYTA. STELARA reduced the segment’s operational growth by approximately 690 basis points, while SIMPONI/SIMPONI ARIA, REMICADE, OPSUMIT/OPSYNVI and IMBRUVICA were additional offsets.

MedTech’s 2.5% operational growth was led by electrophysiology and Shockwave products in Cardiovascular, contact lenses in Vision and trauma products in Orthopaedics. Its slower growth relative to Innovative Medicine limited the breadth of the company’s overall expansion.

Special Charges and Higher R&D Broke the Link Between Sales and Profit

GAAP other expense reached $5.780 billion, compared with other income of $478 million in the prior-year quarter. The non-GAAP reconciliation identified $5.519 billion of pretax litigation-related adjustments, primarily reflecting the proposed talc litigation resolution. The company also said reported EPS reflected the Firefly Bio acquisition and Sail Biomedicines collaboration.

Underlying expense pressure extended beyond these special items. Cost of products sold rose 10.9%, faster than sales, reducing gross margin by approximately 150 basis points. R&D expense increased 26.7% to $4.652 billion and rose to 18.3% of sales from 15.3%, while in-process R&D impairments totaled $339 million. Selling, marketing and administrative expense rose 6.1%, but remained unchanged at 24.7% of sales.

Consequently, adjusted pretax earnings declined 9.1% to $7.672 billion even after specified special items were excluded. A lower adjusted effective tax rate of 17.4%, versus 19.4% a year earlier, partly softened the decline in adjusted net earnings.

Year-to-Date Free Cash Flow Rose Despite Earnings Pressure

Estimated free cash flow for the first nine months of 2026 was approximately $15.1 billion, up about 6.1% from $14.226 billion in the comparable period. This is a year-to-date figure rather than a standalone Q3 cash flow measure. Johnson & Johnson defines free cash flow as operating cash flow less additions to property, plant and equipment.

Full-Year 2026 Guidance

Johnson & Johnson raised the lower ends and midpoints of its sales and adjusted EPS outlooks. The company does not provide forward-looking GAAP earnings guidance because legal proceedings, acquisition costs, unusual gains and losses, and purchase-accounting adjustments cannot be predicted with reasonable certainty.

Management Perspective

CEO Joaquin Duato attributed the sequential acceleration to momentum across the company’s focused portfolio. Management highlighted the market authorization of the OTTAVA robotic surgical system, IMAAVY’s approval for warm autoimmune hemolytic anemia and priority review for RYBREVANT FASPRO in advanced head and neck cancer. Duato also cited strategic investments in higher-growth areas as supporting management’s longer-term growth objectives.

Recent Insider Transactions

Over the latest six-month period in the supplied insider data, seven purchase transactions totaled 239,541 shares and seven sales totaled 269,340 shares, producing net sales of 29,799 shares. The ten latest reported rows consisted of six sales and four derivative-security exercises or conversions, all classified as direct holdings; these records alone do not establish insiders’ views on the company’s outlook.

Risks Investors Need to Watch

• Talc litigation and GAAP earnings visibility: The proposed litigation resolution generated a $5.519 billion pretax adjustment in Q3. Legal uncertainty is also one reason the company does not issue forward-looking GAAP earnings guidance.
• Margin and spending pressure: Cost of products sold grew faster than revenue, gross margin declined, and R&D spending increased 26.7%. Continued pressure in these areas could keep adjusted earnings growth below sales growth.
• Replacement of mature products: STELARA alone reduced Innovative Medicine operational growth by approximately 690 basis points. Growth from newer medicines must continue to offset declines in STELARA and other established products.
• Uneven growth across the portfolio: Innovative Medicine grew 7.7%, compared with 2.5% for MedTech, while U.S. growth of 9.1% materially exceeded international growth of 1.5%.
• Restructuring and separation costs: Q3 adjustments included $369 million related to the Orthopaedics separation. The Innovative Medicine supply-chain restructuring program is expected to cost $650 million to $750 million and continue through fiscal 2029.

Summary

Johnson & Johnson’s Q3 2026 results combined 5.9% sales growth with sharply weaker reported profit and a decline in adjusted earnings. Innovative Medicine and the U.S. market drove the top line, but litigation charges, higher R&D spending and lower gross margin weighed on profitability. Higher year-to-date free cash flow and raised full-year guidance provided a counterweight, while legal costs, margin trends and the company’s ability to replace declining mature products remain the main issues to monitor.